Literature DB >> 28421532

Matrix Metalloproteinase-8 Inhibition Prevents Disruption of Blood-Spinal Cord Barrier and Attenuates Inflammation in Rat Model of Spinal Cord Injury.

Hemant Kumar1,2, Min-Jae Jo1,2, Hyemin Choi1,2, Manjunatha S Muttigi2,3, Seil Shon1, Byung-Joo Kim2, Soo-Hong Lee4, In-Bo Han5.   

Abstract

After spinal cord injury (SCI), tight junction (TJ) protein degradation increases permeability and disrupts the blood-spinal cord barrier (BSCB). The BSCB is primarily formed of endothelial cell, which forms a specialized tight seal due to the presence of TJs. BSCB disruption after SCI allows neutrophil infiltration. Matrix metalloproteinase (MMP)-8 is believed to be mainly expressed by neutrophils and is quickly released upon neutrophil activation. Here, we determined whether MMP-8 is involved in the TJ protein degradation in endothelial cells and also determined its role in the neuroinflammation after SCI. MMP-8 recombinant protein treatment increases the TNF-α expression and decreased the TJ (occludin and zonula occludens-1) protein expression in the endothelial cells. Likewise, specific MMP-8 inhibitor (MMP-8I) significantly prevented the TNF-α-induced decrease in the expression of TJ protein in endothelial cells. Furthermore, MMP-8 expression was significantly increased 1 and 3 days after moderate compression (35 g for 5 min at T10 level) SCI, whereas TJ protein levels decreased as determined qRT-PCR, western blotting, and immunohistochemistry. MMP-8 was inhibited directly using a MMP-8I (5 mg/kg) and indirectly by reducing neutrophil infiltration with sivelestat sodium (50 mg/kg) or using the antioxidant N-acetyl-L-cysteine (100 mg/kg). The MMP-8I significantly decreased TNF-α expression, IL-6, and iNOS expression and increased TJ protein expression after SCI. In addition, MMP-8I significantly lessens the amount of Evans blue dye extravasation observed after injury. Thus, our result suggests that MMP-8 plays an imperative role in inflammation and degradation of TJ proteins. Increased MMP-8 expression was associated with the early inflammatory phase of SCI. Inhibiting MMP-8 significantly attenuated SCI-induced inflammation, BSCB breakdown, and cell injury.

Entities:  

Keywords:  Blood–spinal cord barrier; MMP-8; Neuroinflammation; Occludin; Spinal cord injury; Tight junctions

Mesh:

Substances:

Year:  2017        PMID: 28421532     DOI: 10.1007/s12035-017-0509-3

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  55 in total

Review 1.  The blood-brain barrier/neurovascular unit in health and disease.

Authors:  Brian T Hawkins; Thomas P Davis
Journal:  Pharmacol Rev       Date:  2005-06       Impact factor: 25.468

Review 2.  Astrocyte-endothelial interactions at the blood-brain barrier.

Authors:  N Joan Abbott; Lars Rönnbäck; Elisabeth Hansson
Journal:  Nat Rev Neurosci       Date:  2006-01       Impact factor: 34.870

Review 3.  The blood-brain barrier in health and chronic neurodegenerative disorders.

Authors:  Berislav V Zlokovic
Journal:  Neuron       Date:  2008-01-24       Impact factor: 17.173

4.  Acute inflammatory response in spinal cord following impact injury.

Authors:  S L Carlson; M E Parrish; J E Springer; K Doty; L Dossett
Journal:  Exp Neurol       Date:  1998-05       Impact factor: 5.330

5.  TNF-alpha induced NFκB signaling and p65 (RelA) overexpression repress Cldn5 promoter in mouse brain endothelial cells.

Authors:  Muhammad Aslam; Nafees Ahmad; Rajneesh Srivastava; Bernhard Hemmer
Journal:  Cytokine       Date:  2011-12-03       Impact factor: 3.861

6.  Neutrophils mediate blood-spinal cord barrier disruption in demyelinating neuroinflammatory diseases.

Authors:  Benoit Aubé; Sébastien A Lévesque; Alexandre Paré; Émilie Chamma; Hania Kébir; Roser Gorina; Marc-André Lécuyer; Jorge I Alvarez; Yves De Koninck; Britta Engelhardt; Alexandre Prat; Daniel Côté; Steve Lacroix
Journal:  J Immunol       Date:  2014-07-21       Impact factor: 5.422

Review 7.  Early microvascular reactions and blood-spinal cord barrier disruption are instrumental in pathophysiology of spinal cord injury and repair: novel therapeutic strategies including nanowired drug delivery to enhance neuroprotection.

Authors:  Hari Shanker Sharma
Journal:  J Neural Transm (Vienna)       Date:  2010-12-16       Impact factor: 3.575

Review 8.  Vascular events after spinal cord injury: contribution to secondary pathogenesis.

Authors:  A E Mautes; M R Weinzierl; F Donovan; L J Noble
Journal:  Phys Ther       Date:  2000-07

9.  Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice.

Authors:  Ethan A Winkler; Jesse D Sengillo; Abhay P Sagare; Zhen Zhao; Qingyi Ma; Edward Zuniga; Yaoming Wang; Zhihui Zhong; John S Sullivan; John H Griffin; Don W Cleveland; Berislav V Zlokovic
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-03       Impact factor: 11.205

Review 10.  Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis.

Authors:  Gianfranco Bazzoni; Elisabetta Dejana
Journal:  Physiol Rev       Date:  2004-07       Impact factor: 37.312

View more
  19 in total

1.  5-hydroxytryptamine 1F Receptor Agonist Induces Mitochondrial Biogenesis and Promotes Recovery from Spinal Cord Injury.

Authors:  Epiphani C Simmons; Natalie E Scholpa; Kristan H Cleveland; Rick G Schnellmann
Journal:  J Pharmacol Exp Ther       Date:  2019-11-27       Impact factor: 4.030

2.  Chronic spinal cord changes in a high-fat diet-fed male rat model of thoracic spinal contusion.

Authors:  Redin A Spann; William J Lawson; Raymond J Grill; Michael R Garrett; Bernadette E Grayson
Journal:  Physiol Genomics       Date:  2017-08-18       Impact factor: 3.107

3.  Pharmacologic treatment with OKN-007 reduces alpha-motor neuron loss in spinal cord of aging mice.

Authors:  Katarzyna M Piekarz; Constantin Georgescu; Jonathan D Wren; Rheal A Towner; Holly Van Remmen
Journal:  Geroscience       Date:  2022-01-04       Impact factor: 7.713

4.  Lab-Attenuated Rabies Virus Facilitates Opening of the Blood-Brain Barrier by Inducing Matrix Metallopeptidase 8.

Authors:  An Fang; Yueming Yuan; Fei Huang; Caiqian Wang; Dayong Tian; Rui Zhou; Ming Zhou; Huanchun Chen; Zhen F Fu; Ling Zhao
Journal:  J Virol       Date:  2022-08-25       Impact factor: 6.549

Review 5.  Therapeutic targets and nanomaterial-based therapies for mitigation of secondary injury after spinal cord injury.

Authors:  Jun Gao; Minkyung Khang; Zhen Liao; Megan Detloff; Jeoung Soo Lee
Journal:  Nanomedicine (Lond)       Date:  2021-08-17       Impact factor: 6.096

Review 6.  Angiogenesis in Spinal Cord Injury: Progress and Treatment.

Authors:  Konstantinos Tsivelekas; Dimitrios Stergios Evangelopoulos; Dimitrios Pallis; Ioannis S Benetos; Stamatios A Papadakis; John Vlamis; Spyros G Pneumaticos
Journal:  Cureus       Date:  2022-05-30

7.  Resolvin D3 Promotes Inflammatory Resolution, Neuroprotection, and Functional Recovery After Spinal Cord Injury.

Authors:  Juri Kim; Hari Prasad Joshi; Seung Hun Sheen; Kyoung-Tae Kim; Jae Won Kyung; Hyemin Choi; Ye Won Kim; Su Yeon Kwon; Eun Ji Roh; Un Yong Choi; Seil Sohn; Yong Ho Kim; Chul-Kyu Park; Hemant Kumar; In-Bo Han
Journal:  Mol Neurobiol       Date:  2020-09-22       Impact factor: 5.590

8.  FDA-approved 5-HT1F receptor agonist lasmiditan induces mitochondrial biogenesis and enhances locomotor and blood-spinal cord barrier recovery after spinal cord injury.

Authors:  Epiphani C Simmons; Natalie E Scholpa; Rick G Schnellmann
Journal:  Exp Neurol       Date:  2021-04-10       Impact factor: 5.620

9.  Interleukin-17A Contributed to the Damage of Blood-CNS Barriers During Streptococcus suis Meningitis.

Authors:  Lei Xu; Xi Lu; Peng Xiao; Ran Liu; Kunlong Xia; Meizhou Wu; Meilin Jin; Anding Zhang
Journal:  Mol Neurobiol       Date:  2022-01-19       Impact factor: 5.682

Review 10.  Neutrophil, Extracellular Matrix Components, and Their Interlinked Action in Promoting Secondary Pathogenesis After Spinal Cord Injury.

Authors:  Sonam Dolma; Hemant Kumar
Journal:  Mol Neurobiol       Date:  2021-06-22       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.